Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

HIV Medicine

Volumn 16, Issue 8, 2015, Pages 477-484

  Verloes, R ^a   Deleu, S ^b   Niemeijer, N ^a   Crauwels, H ^a   Meyvisch, P ^a   Williams, P ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Janssen Clinical Pharmacology Unit   (Belgium)

Author keywords

HIV; Long acting formulation; Nonnucleoside reverse transcriptase inhibitor; Pharmacokinetics; Rilpivirine

Indexed keywords

RILPIVIRINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAYED RELEASE FORMULATION; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; INJECTION SITE REACTION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN CORPUSCULAR HEMOGLOBIN; MUSCULOSKELETAL STIFFNESS; NORMAL HUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; POSTCONCUSSION SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AREA UNDER THE CURVE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HIV INFECTIONS; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RILPIVIRINE; YOUNG ADULT;

EID: 84938742453     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12247     Document Type: Article

References (29)

1. Edurant(rilpivirine) tablets, US prescribing information. Janssen-Cilag, 2011; Revised May 2014. Available at http://www.edurant.com/sites/www.edurant-info.com.hcp/files/EDURANT-PI.pdf (accessed 30 September 2014).
2. Edurant(rilpivirine) tablets, EU summary of product characteristics. Janssen-Cilag, 2011; Revised March 2014. Available at http://www.medicines.org.uk/EMC/medicine/25490/SPC/Edurant+25+mg+tablets/#DOC (accessed 30 September 2014).
3. COMPLERA™ (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, full prescribing information. Gilead Sciences 2011. Revised September 2014. Available at http://www.gilead.com/pdf/complera_pi.pdf (accessed 30 September 2014).
4. EVIPLERA 200mg/25mg/245mg film-coated tablets, summary of product characteristics. Gilead Sciences 2011. Revised September 2014. Available at http://www.medicines.org.uk/emc/medicine/25518/SPC/ (accessed 30 September 2014).
5. Cohen CJ, Andrade-Villanueva J, Clotet B etal. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-237.
6. Molina JM, Cahn P, Grinsztejn B etal. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-246.
7. Cohen C, Molina JM, Cahn P etal. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60: 33-42.
8. Cohen C, Molina JM, Cassetti I etal. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two phase III randomized trials. AIDS 2013; 27: 939-950.
9. DHHS guidelines: panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated May 1 2014. Available at http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (accessed 30 September 2014).
10. EACS guidelines: EACS European Guidelines for treatment of HIV infected adults in Europe. Version 7.02, June 2014. Available at http://www.eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf (accessed 30 September 2014).
11. Bennett DE, Jordan MR, Bertagnolio S etal. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 2012; 54 (Suppl 4): S280-S289.
12. Draper BH, Morrioni C, Hoffman M etal. Depot medroxyprogesterone versus norethisterone oenanthate for long acting progestogenic contraception. Cochrane Database Syst Rev 2006; (3)CD005214.
13. Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol 2014; 9: 310-317.
14. Verloes R, van't Klooster G, Baert L etal. TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. 17th International AIDS Conference. Mexico City, Mexico, July, 2008 [Abstract TUPE0042].
15. Spreen W, Margolis DA, Pottage JC. Long-acting injectable antivirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8: 565-571.
16. Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 2013; 8: 50-58.
17. Parboosing R, Maguire GEM, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 2012; 4: 488-520.
18. Kanmogne GD, Singh S, Roy U etal. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine 2012; 7: 2373-2388.
19. McDonald TO, Giardiello M, Martin P etal. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthc Mater 2014; 3: 400-411.
20. Baert L, van't Klooster G, Dries W etal. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009; 72: 502-508.
21. van't Klooster G, Hoeben E, Borghys H etal. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54: 2042-2050.
22. van't Klooster G, Verloes R, Baert L etal. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February, 2008 [Abstract 134].
23. Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol 2013; 53: 834-840.
24. Crauwels HM, von Schaick E, van Heeswijk RPG, Vanveggel S, Boven K, Vis P. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE. 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November, 2010 [Abstract P186].
25. Jackson AG, Else LJ, Mesquita PM etal. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther 2014; 96: 314-323.
26. Williams J, Sayles HR, Meza JL etal. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond) 2013; 8: 1807-1813.
27. Ford SL, Gould E, Chen S etal. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013; 57: 5472-5477.
28. Spreen W, Williams P, Margolis D etal. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults. 7th Annual IAS Conference. Kuala Lumpur, Malaysia, June, 2013 [Abstract WEAB0103].
29. Margolis D, Brinson C, Eron J etal. 744 and rilpivirine as two-drug oral maintenance therapy: LAI116482 (LATTE) week 48 results. 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, March, 2014 [Abstract 91LB].